Barclays upgraded Evonik (EVKIF) to Overweight from Equal Weight with a price target of EUR 17, up from EUR 16. The firm says its prior concerns of price normalization in methionine has reversed into a positive catalyst with supply disruptions in Asia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVKIF: